DSM Capital Partners LLC Makes New $56,000 Investment in Zoetis Inc. (NYSE:ZTS)

DSM Capital Partners LLC bought a new position in shares of Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 282 shares of the company’s stock, valued at approximately $56,000.

Other institutional investors also recently bought and sold shares of the company. Blue Bell Private Wealth Management LLC lifted its position in shares of Zoetis by 222.5% in the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares in the last quarter. Independence Bank of Kentucky lifted its position in shares of Zoetis by 371.4% in the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares in the last quarter. Private Wealth Management Group LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at $33,000. Ramirez Asset Management Inc. purchased a new stake in shares of Zoetis in the third quarter valued at $35,000. Finally, Gladius Capital Management LP acquired a new position in Zoetis in the fourth quarter valued at $40,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently commented on ZTS. Barclays dropped their target price on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Piper Sandler reiterated an “overweight” rating and issued a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. HSBC dropped their target price on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Finally, Stifel Nicolaus dropped their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, April 30th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $211.75.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the transaction, the executive vice president now owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Zoetis Stock Down 0.5 %

Shares of ZTS stock traded down $0.83 during trading hours on Friday, reaching $170.07. The company had a trading volume of 1,893,824 shares, compared to its average volume of 2,946,235. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The company has a market capitalization of $77.60 billion, a P/E ratio of 32.77, a price-to-earnings-growth ratio of 2.64 and a beta of 0.86. The stock’s fifty day simple moving average is $164.11 and its 200 day simple moving average is $179.70.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The company’s revenue for the quarter was up 9.5% compared to the same quarter last year. As a group, sell-side analysts expect that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.